ClinicalTrials.gg
RecruitingNCT07726368Updated Sep 10, 2026

Study of ECC4703 With Sulfasalazine and Pitavastatin

A Phase 1 interventional study of ECC4703 and Sulfasalazine in Non-alcoholic Fatty Liver Disease (NAFLD) and Dyslipidaemia, sponsored by Eccogene. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Eccogene · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Non-alcoholic Fatty Liver Disease with a site in Australia — 8 open to participants now, 12 under way, 10 of them phase 3. Non-alcoholic Fatty Liver Disease · Australia.

Planned enrollment
49th of 54
40 · median 264
Started
2026
with 1 other
Phase 1
15 of 54
2 open now
Primary completion
2026-12
later than 2 of 11 live
Registered
53rd of 54
by date
Lead sponsor
3 of 54
Eccogene

Among the 54 studies in Non-alcoholic Fatty Liver Disease with a site in Australia, this one is the 49th largest by planned enrollment, is one of 2 that started in 2026, is one of 15 in phase 1, reaches primary completion later than 2 of the 11 other live ones, and was the 53rd registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

8 of the 54 studies in Non-alcoholic Fatty Liver Disease with a site in Australia are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Non-alcoholic Fatty Liver Disease with a site in Australia, or all of them as a file.
02

Study summary

Non-alcoholic fatty liver disease is a chronic, serious, life-threatening, inflammatory liver disease characterized by increased liver fat content, inflammation, and progressive fibrosis. The overall prevalence of non-alcoholic fatty liver disease is rapidly rising world-wide.

ECC4703 is a potential new treatment for non-alcoholic fatty liver disease.

The purpose of this research is to investigate the safety, tolerability and pharmacokinetics of sulfasalazine and pitavastatin when combined with ECC4703.

03

Conditions studied

  • Non-alcoholic Fatty Liver Disease (NAFLD)
  • Dyslipidaemia

Keywords

  • BCRP inhibitor
  • OATP inhibitor
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female between the ages of 18 and 65 years, inclusive, at the time of Screening.
  • Are healthy and in the opinion of the Investigator have an acceptable medical history (free from significant cardiac, pulmonary, gastrointestinal, hepatic, renal, haematological, neurological, infective, or psychiatric diseases as determined by medical history over the past 5 years, physical examination, vital signs, 12-lead , and clinical laboratory tests).
  • Has not consumed and agrees to abstain from taking any prescription drugs or non-prescription drugs for 7 days or 5 half-lives (whichever is longer) prior to first dose of trial treatment and continuing through end of the Treatment Period.

Exclusion criteria

Exclusion Criteria:

  • Has a history of significant renal, hepatic, cardiovascular, psychiatric, neoplastic, thyroid disease/abnormality or other disease which, in the opinion of the Investigator, represents a safety risk for taking part in the trial.
  • Has a history of sensitivity to any of the trial treatments (and/or their ), or severe drug or other allergy
  • Has a history of drug abuse within the previous 2 years, or a positive drug screen at Screening and/or Day -1.
  • Regular consumption of more than 10 standard alcoholic drinks/week and/or more than 4 standard alcoholic drinks on any one day
  • Has a history or current diagnosis of a significant psychiatric disorder that would, in the opinion of the Investigator, affect the participant's ability to comply with the trial requirements.
  • Has a personal or family history of hereditary muscular disorders, previous statin-induced myopathy/rhabdomyolysis, or unexplained repeated or severe muscle pain.
  • Has a history of any unexplained chronic skin rash or skin diseases.
  • Has a personal or family history of Stevens-Johnson syndrome (SJS), or other severe drug-induced skin reactions.
  • History of surgery or hospitalisation within 3 months prior to screening, or surgery planned during the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Cohort 1 - ECC4703 and Sulfasalazine

    Cohort 1 participants will receive ECC4703 and sulfasalazine.

    Drug: ECC4703 · Drug: Sulfasalazine

  • Experimental
    Cohort 2 - ECC4703 and Pitavastatin

    Cohort 2 participants will receive ECC4703 and pitavastatin.

    Drug: ECC4703 · Drug: Pitavastatin

Interventions

  • ECC4703 will be administered orally.

  • Sulfasalazine will be administered orally.

  • Pitavastatin will be administered orally.

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration of sulfasalazine in the blood of participants who have taken ECC4703 (as part of called pharmacokinetic or 'PK' testing)

    Time frame: Blood samples for PK testing of sulfasalazine will be collected on Days 1, 2, 3, 4, 9, 10, 11 and 12

  2. Time to maximum plasma concentration of sulfasalazine in the blood of participants who have taken ECC4703 (as part of called pharmacokinetic or 'PK' testing)

    Time frame: Blood samples for PK testing of sulfasalazine will be collected on Days 1, 2, 3, 4, 9, 10, 11 and 12

  3. Area under the drug concentration-time curve of sulfasalazine in the blood of participants who have taken ECC4703 (as part of called pharmacokinetic or 'PK' testing)

    Time frame: Blood samples for PK testing of sulfasalazine will be collected on Days 1, 2, 3, 4, 9, 10, 11 and 12

  4. Clearance of sulfasalazine in the blood of participants who have taken ECC4703 (as part of called pharmacokinetic or 'PK' testing)

    Time frame: Blood samples for PK testing of sulfasalazine will be collected on Days 1, 2, 3, 4, 9, 10, 11 and 12

  5. Maximum plasma concentration of pitavastatin in the blood of participants who have taken ECC4703 (as part of called pharmacokinetic or 'PK' testing)

    Time frame: Blood samples for PK testing of pitavastatin will be collected on Days 1, 2, 3, 4, 9, 10, 11 and 12

  6. Time to maximum plasma concentration of pitavastatin in the blood of participants who have taken ECC4703 (as part of called pharmacokinetic or 'PK' testing)

    Time frame: Blood samples for PK testing of pitavastatin will be collected on Days 1, 2, 3, 4, 9, 10, 11 and 12

  7. Area under the drug concentration-time curve of pitavastatin in the blood of participants who have taken ECC4703 (as part of called pharmacokinetic or 'PK' testing)

    Time frame: Blood samples for PK testing of pitavastatin will be collected on Days 1, 2, 3, 4, 9, 10, 11 and 12

  8. Clearance of pitavastatin in the blood of participants who have taken ECC4703 (as part of called pharmacokinetic or 'PK' testing)

    Time frame: Blood samples for PK testing of pitavastatin will be collected on Days 1, 2, 3, 4, 9, 10, 11 and 12

Secondary outcomes

  1. Number of participants with Adverse Events (AEs), as assessed by a 5-point scale, CTCAE v5.0

    Adverse event monitoring includes measuring the frequency, severity and relationship of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) leading to treatment or study discontinuation. Severity of adverse events will be characterised from 1 (mild) to 5 (death).

    Time frame: From baseline to follow-up visit (on Day 19).

  2. Change from Baseline in blood pressure, measured using a sphygmomanometer via a cuff on the arm

    Time frame: From baseline to follow-up visit (on Day 19).

  3. Change from Baseline in heart rate, measured in beats-per-minute by a vital signs machine

    Time frame: From Baseline to follow-up visit (on Day 19).

  4. Change from Baseline in respiratory rate, measured in breaths-per-minute manually via a 60-second count

    Time frame: From Baseline to follow-up visit (on Day 19).

  5. Change from Baseline in body temperature in degrees Celsius, measured using a thermometer

    Time frame: From Baseline to follow-up visit (on Day 19).

  6. Changes from Baseline in Clinical Laboratory Parameters including, but not limited to, haematology and blood chemistry.

    Blood samples will be collected. All safety laboratory assessments will be assessed by a certified local laboratory, using that laboratory's normal ranges. Any clinically significant changes will be recorded as Adverse Event (AE). The severity of each AE (and SAE or Serious Adverse Event) will be graded using a 5-point scale

    Time frame: From baseline to follow-up visit (on Day 19)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2026, 4 months after the start.

Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 4 months is below that.

Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2026
First posted
Jul 24, 2026
StartActual
Aug 7, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07726368
Lead sponsor
Eccogene
Responsible party
Sponsor
First posted
Jul 24, 2026
Start date
Aug 7, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 10, 2026

Study contacts

Eccogene Clinical Trials
Contact
contact@eccogene.com
86-21-61053022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: ECC4703 · Sulfasalazine · Pitavastatin

Start the discussion